期刊文献+

分析老年矽肺结核病的耐药水平与临床治疗 被引量:5

The research of drug resistance gene in Old Silicosis Mycobacterium tuberculosis
下载PDF
导出
摘要 目的分析老年矽肺结核病的耐药水平和7种耐药基因突变情况。方法 117例老年矽肺结核患者的临床分离株均做传统梯度药敏试验和聚合酶链反应-单链构象多态性(PCR-SSCP)分析。结果被测菌株传统药敏试验耐药率82.1%。7种耐药基因[链霉素(rpsL)、利福平(rpoB)、异烟肼(katG)、乙胺丁醇(embB)、吡嗪酰胺(pncA)、喹诺酮(gyrA)、卡那霉素(km)]突变率分别为78.1%、65.6%、52%、33.3%、37.5%、54.1%、28.1%。结论传统梯度药敏试验与7种耐药基因联合检测,证实耐药基因突变与耐药水平和治疗关系密切。 Objective To study the relationship between drug-resistance gene mutation and drug-resistance level in OLD Silicosis M.tuberculosis.Methods 117 M.tuberculosis strains isolated from clinical sputum specimens were analyzed by PCR-SSCP and traditional drug susceptibility tests.Results The gene mutation rate of SM(rpsL),REP(rpoB),INH(katG),EMB(embB),PZA(pncA),Quinolones(gyrA) and KM(km) resistance of isolated strains were 78.1%,65.6%,52%,33.3%,37.5%,54.1% and 28.1%.Conclusion The gene mutation was is closely related to drug resistance level of M.tuberculosis.
机构地区 中国人民解放军
出处 《临床肺科杂志》 2012年第6期1057-1059,共3页 Journal of Clinical Pulmonary Medicine
基金 国家重大传染病防治专项课题项目编号:2012ZX10005007-011
关键词 结核杆菌 药敏试验 聚合酶链反应多态-单链构象多态性 Silicosis M.tuberculosis drug-resistance PCR-SSCP
  • 相关文献

参考文献5

  • 1Speech at the Ministerial Meeting of High M/XDR-TB Burden Countries. Minister Chen Zhu, 1April, 2009. http://www, who. int/tb_ beijingmeetingcZmedia/press _ pack/presentations/chenzhu _ speech mdr_en, pdf. Accessed June 2010.
  • 2李洪敏,安慧茹,王巍,苗青,张霞.结核病治疗前后耐喹诺酮(gyrA)基因的变化分析[J].临床肺科杂志,2010,15(1):16-17. 被引量:1
  • 3姜英,彭俊平,杨帆,余黎,王玉琳,金奇.结核分枝杆菌耐吡嗪酰胺分子机制研究[J].微生物学免疫学进展,2007,35(1):5-9. 被引量:12
  • 4WHO Muhidrug and extensively drug-resistant TB (M/XDR-TB) : 2010 global report on surveillance and response. WHO/HTM/TB/ 2010.3. Geneva, Switzerland: World Health Organization. 2010. ppl - 70.
  • 5Faustini A, Hall AJ. Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe : a systematic review [ J ]. Thorax, 2006,61 : 158 - 163.

二级参考文献14

  • 1Takiff EL, Salazar, Guerrern WM,et al. Cloning and nucleotide sequece of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Agents Chemother. 1994; 38:773 - 780.
  • 2Alangaden GJ, Manavathu EK, et al. Characterization of fluoroquinolone-resistant mutant strains of mycobacterium tuberculosis selected in the laboratory and isolated from patients. Atimicrobial agents and chemotherapy, 1995,39 ( 8 ) : 1.
  • 3Ramaswamy s,Mussor JM.Molecular genetic basis of antimicrobial agent resisatance in Mycobacterium tuberculosis:1998 update[J].Tubercle and lung Disease 1998,79(1):3-29.
  • 4Scorpio A,Lindholm LP,Heifets L,et al.Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis[J].Antimicrobial Agents and Chemotherapy 1997,41(3):540-543.
  • 5Morlock GP,Crawford JT,Butler WR,et al.Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis[J].Antimicrobial Agents and Chemotherapy 2000,44(9):2291-2295.
  • 6Sreevatsan S,Pan X,Zhang Y,et al.Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms[J].Antimicrobial Agents and Chemotherapy 1997,41(3):636-640.
  • 7Hirano K,Takahashi M,Fukasawa Y,et al.Mutations in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis[J].Tubercle and Lung Disease 1998,78(2):117-122.
  • 8Cheng SJ,Thibert L,Sanchez T,et at.pncA Mutations as a major mechanism of pyrazinamide Resistance in Mycobacterium tuberculosis:spread of a monoresistant strain in Quebec,Canada[J].Antimicrobial Agents and Chemotherapy 2000,44(3):528-532.
  • 9Marttila HJ,Marjamaki M,Vyshenvskaya E,et al.pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia[J].Antimicrobial Agents and Chemotherapy 1999,43(7);1764-1766.
  • 10Heifets L,lindholm LP.Pyrazinamide sterilizing activity in vitro against semi-dormant Mycobacterium tuberculosis bacterial populations[J].Am Rev Respir Dis 1992,145:1223-1225.

共引文献11

同被引文献40

  • 1黄祥洪.矽肺致肺心病并发症及伴发症临床分析[J].浙江临床医学,1999,1(6):397-398. 被引量:1
  • 2胡志平,林丽.矽肺患者生存质量及其影响因素的调查分析[J].工业卫生与职业病,2006,32(1):29-31. 被引量:10
  • 3周为鸿.结核诊断金标准探讨[J].实用诊断与治疗杂志,2006,20(10):741-742. 被引量:27
  • 4赵此述,陈仁,卞志强.现代临床免疫学[M].北京:人民军医出版社,1994:683-696.
  • 5朱元珏 陈文彬.呼吸病学[M].北京:人民卫生出版社,2002.609-616.
  • 6中华医学会.临床诊疗指南,结核病分册[M].北京:人民卫生出版社,2004.122.
  • 7赵莉莎.矽肺合并胸腔积液1例[J].中国实用内科杂志,1996,16(9):562-562.
  • 8Nasrullah M,Mazurek JM,Wood JM,et al.Silicosis mortality with respiratory tuberculosis in the United States,1968-2006[J].Am J Epidemiol,2011,174(7):839-848.
  • 9Chaudhury N,Paliwal R,Phatak A,et al.Co-morbidities among silicotics at Shakarpur:A follow up study[J].Lung India,2012,29(1):6-10.
  • 10Lanzas F, Karakousis PC, Sacchettini JC,et al. Multidrug-resistant tuberculosis in panama is driven by clonal expansiion of a multi- drug-resistant mycobacterium tuberculosis strain related to the KZN extensively drug-resistant m. tuberculosis strain from South Africa [ J ]. Journal of Clinical Microbiology,2013,51 (10) :3277 - 3285.

引证文献5

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部